WO1999057266A3 - Immunosuppression by blocking t cell co-stimulation signal 2 (b7/cd28 interaction) - Google Patents
Immunosuppression by blocking t cell co-stimulation signal 2 (b7/cd28 interaction) Download PDFInfo
- Publication number
- WO1999057266A3 WO1999057266A3 PCT/GB1999/001350 GB9901350W WO9957266A3 WO 1999057266 A3 WO1999057266 A3 WO 1999057266A3 GB 9901350 W GB9901350 W GB 9901350W WO 9957266 A3 WO9957266 A3 WO 9957266A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- recipient
- cells
- cell
- interaction
- stimulation
- Prior art date
Links
- 230000003993 interaction Effects 0.000 title abstract 3
- 230000000903 blocking effect Effects 0.000 title abstract 2
- 206010062016 Immunosuppression Diseases 0.000 title 1
- 230000020385 T cell costimulation Effects 0.000 title 1
- 230000001506 immunosuppresive effect Effects 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 6
- 210000004027 cell Anatomy 0.000 abstract 5
- 108010021064 CTLA-4 Antigen Proteins 0.000 abstract 3
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 abstract 3
- 210000000056 organ Anatomy 0.000 abstract 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 abstract 2
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 abstract 2
- 239000003446 ligand Substances 0.000 abstract 2
- 102000043131 MHC class II family Human genes 0.000 abstract 1
- 108091054438 MHC class II family Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Transplantation (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Devices Affording Protection Of Roads Or Walls For Sound Insulation (AREA)
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ507706A NZ507706A (en) | 1998-04-30 | 1999-04-30 | Immunosuppression by blocking T cell co-stimulation signal 2 (B7/CD28 interaction) |
AU37213/99A AU772239B2 (en) | 1998-04-30 | 1999-04-30 | Immunosuppression by blocking T cell co-stimulation signal 2 (B7/CD28 interaction) |
EP99919418A EP1073737B1 (en) | 1998-04-30 | 1999-04-30 | Immunosuppression by blocking t cell co-stimulation signal 2 (b7/cd28 interaction) |
DE69935318T DE69935318T2 (en) | 1998-04-30 | 1999-04-30 | IMMUNE RESTRICTION THROUGH BLOCKING OF T-CELL COSTIMULATION SIGNAL 2 (B7 / CD28 INTERACTION) |
JP2000547221A JP2002513568A (en) | 1998-04-30 | 1999-04-30 | Immunosuppression by blocking T cell costimulatory signal 2 (B7 / CD28 interaction) |
US09/674,462 US7432344B1 (en) | 1998-04-30 | 1999-04-30 | Porcine CTLA-4 for xenograft-specific immunosuppression |
CA2326671A CA2326671C (en) | 1998-04-30 | 1999-04-30 | Immunosuppression by blocking t cell co-stimulation signal 2 (b7/cd28 interaction) |
US12/231,608 US8097598B2 (en) | 1998-04-30 | 2008-09-04 | Porcine CTLA-4 for xenograft-specific immunosuppression |
US13/316,791 US9090708B2 (en) | 1998-04-30 | 2011-12-12 | Porcine CTLA-4 for xenograft-specific immunosuppression |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9809280.2A GB9809280D0 (en) | 1998-04-30 | 1998-04-30 | Immunosupression |
GB9809280.2 | 1998-04-30 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/674,462 A-371-Of-International US7432344B1 (en) | 1998-04-30 | 1999-04-30 | Porcine CTLA-4 for xenograft-specific immunosuppression |
US12/231,608 Continuation US8097598B2 (en) | 1998-04-30 | 2008-09-04 | Porcine CTLA-4 for xenograft-specific immunosuppression |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999057266A2 WO1999057266A2 (en) | 1999-11-11 |
WO1999057266A3 true WO1999057266A3 (en) | 2000-04-20 |
Family
ID=10831274
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1999/001350 WO1999057266A2 (en) | 1998-04-30 | 1999-04-30 | Immunosuppression by blocking t cell co-stimulation signal 2 (b7/cd28 interaction) |
Country Status (11)
Country | Link |
---|---|
US (3) | US7432344B1 (en) |
EP (2) | EP1073737B1 (en) |
JP (2) | JP2002513568A (en) |
AT (1) | ATE355373T1 (en) |
AU (1) | AU772239B2 (en) |
CA (1) | CA2326671C (en) |
DE (1) | DE69935318T2 (en) |
ES (1) | ES2284251T3 (en) |
GB (1) | GB9809280D0 (en) |
NZ (2) | NZ507706A (en) |
WO (1) | WO1999057266A2 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9809280D0 (en) * | 1998-04-30 | 1998-07-01 | Rpms Technology Ltd | Immunosupression |
US7030228B1 (en) | 1999-11-15 | 2006-04-18 | Miltenyi Biotec Gmbh | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby |
EP1274733A1 (en) * | 2000-04-12 | 2003-01-15 | Genetics Institute, Inc. | Surface-bound antigen binding portions of antibodies that bind to ctla-4 and cd28 and uses therefor |
KR100889887B1 (en) * | 2000-05-26 | 2009-03-24 | 브리스톨-마이어스스퀴브컴파니 | Soluble CTLA4 Mutant Molecules and Uses Thereof |
US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
CN1911965B (en) * | 2001-01-17 | 2013-05-29 | 新兴产品开发西雅图有限公司 | Binding domain-immunoglobulin fusion proteins |
ITRM20010408A1 (en) | 2001-07-10 | 2003-01-10 | Univ Napoli Federico Ii | CYTOTOXIC HUMAN MINI-ANTIBODY FOR CANCER CELLS THAT EXPRESS THE ERBB2 RECEPTOR. |
US7601351B1 (en) | 2002-06-26 | 2009-10-13 | Human Genome Sciences, Inc. | Antibodies against protective antigen |
EP1539235A2 (en) | 2002-07-01 | 2005-06-15 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
WO2005009134A1 (en) | 2003-07-21 | 2005-02-03 | Lifecell Corporation | ACELLULAR TISSUE MATRICES MADE FROM GALACTOSE α-1,3-GALACTOSE-DEFICIENT TISSUE |
KR20070002057A (en) | 2004-03-17 | 2007-01-04 | 레비비코르 인코포레이션 | Tissue products derived from animals lacking any expression of functional alpha 1,3 galactosyltransferase |
CA3079874C (en) | 2004-10-22 | 2023-01-03 | Revivicor, Inc. | Ungulates with genetically modified immune systems |
UA97469C2 (en) | 2005-07-25 | 2012-02-27 | Емерджент Продакт Дівелопмент Сіетл, Елелсі | Humanized cd37-specific binding immunoglobulin molecule |
AU2006292827B2 (en) | 2005-08-09 | 2013-02-14 | Revivicor, Inc. | Transgenic ungulates expressing CTLA4-IG and uses thereof |
NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
NZ603059A (en) | 2008-04-11 | 2014-07-25 | Emergent Product Dev Seattle | Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof |
WO2010051288A1 (en) | 2008-10-27 | 2010-05-06 | Revivicor, Inc. | Immunocompromised ungulates |
EP2464219B1 (en) | 2009-08-14 | 2019-10-23 | Revivicor, Inc. | Multi-transgenic pigs for diabetes treatment |
US9420770B2 (en) | 2009-12-01 | 2016-08-23 | Indiana University Research & Technology Corporation | Methods of modulating thrombocytopenia and modified transgenic pigs |
CN106432474A (en) | 2010-03-12 | 2017-02-22 | 艾伯维生物医疗股份有限公司 | CTLA4 proteins and their uses |
ES2680636T3 (en) | 2011-02-14 | 2018-09-10 | Revivicor Inc. | Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof |
US20140115728A1 (en) | 2012-10-24 | 2014-04-24 | A. Joseph Tector | Double knockout (gt/cmah-ko) pigs, organs and tissues |
US9944689B2 (en) * | 2013-03-07 | 2018-04-17 | The General Hospital Corporation | Human CTLA4 mutants and use thereof |
AU2014341866B2 (en) | 2013-11-04 | 2018-07-05 | Lifecell Corporation | Methods of removing alpha-galactose |
CA2996652A1 (en) * | 2015-09-01 | 2017-03-09 | Immunwork Inc. | Molecular constructs for preventing the formation of blood clot and/or treating thrombosis |
US11352426B2 (en) | 2015-09-21 | 2022-06-07 | Aptevo Research And Development Llc | CD3 binding polypeptides |
CN111214646B (en) * | 2019-12-30 | 2023-08-01 | 中山大学·深圳 | Application of PD-L1/CTLA-4 in preparation of immunosuppressant |
JP2023551404A (en) | 2020-11-20 | 2023-12-08 | レビビコア, インコーポレイテッド | Multiple transgenic pigs with growth hormone receptor knockout for cross-species transplantation |
US20230255185A1 (en) | 2021-09-20 | 2023-08-17 | Revivicor, Inc. | Multitransgenic pigs comprising ten genetic modifications for xenotransplantation |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995034320A2 (en) * | 1994-06-07 | 1995-12-21 | Regents Of The University Of Minnesota | Methods for inhibiting antigen specific t cell responses |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2222055A1 (en) * | 1995-05-23 | 1996-11-28 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Multimeric proteins |
EP0892643B2 (en) * | 1996-03-20 | 2009-09-02 | Bristol-Myers Squibb Company | Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith |
US6165476A (en) * | 1997-07-10 | 2000-12-26 | Beth Israel Deaconess Medical Center | Fusion proteins with an immunoglobulin hinge region linker |
GB9809280D0 (en) * | 1998-04-30 | 1998-07-01 | Rpms Technology Ltd | Immunosupression |
-
1998
- 1998-04-30 GB GBGB9809280.2A patent/GB9809280D0/en not_active Ceased
-
1999
- 1999-04-30 ES ES99919418T patent/ES2284251T3/en not_active Expired - Lifetime
- 1999-04-30 JP JP2000547221A patent/JP2002513568A/en active Pending
- 1999-04-30 US US09/674,462 patent/US7432344B1/en not_active Expired - Fee Related
- 1999-04-30 CA CA2326671A patent/CA2326671C/en not_active Expired - Lifetime
- 1999-04-30 NZ NZ507706A patent/NZ507706A/en not_active IP Right Cessation
- 1999-04-30 DE DE69935318T patent/DE69935318T2/en not_active Expired - Lifetime
- 1999-04-30 WO PCT/GB1999/001350 patent/WO1999057266A2/en active IP Right Grant
- 1999-04-30 EP EP99919418A patent/EP1073737B1/en not_active Expired - Lifetime
- 1999-04-30 NZ NZ527297A patent/NZ527297A/en active IP Right Revival
- 1999-04-30 AU AU37213/99A patent/AU772239B2/en not_active Expired
- 1999-04-30 AT AT99919418T patent/ATE355373T1/en not_active IP Right Cessation
- 1999-04-30 EP EP06077284A patent/EP1854884A3/en not_active Withdrawn
-
2008
- 2008-09-04 US US12/231,608 patent/US8097598B2/en not_active Expired - Fee Related
-
2011
- 2011-04-22 JP JP2011096600A patent/JP5706225B2/en not_active Expired - Lifetime
- 2011-12-12 US US13/316,791 patent/US9090708B2/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995034320A2 (en) * | 1994-06-07 | 1995-12-21 | Regents Of The University Of Minnesota | Methods for inhibiting antigen specific t cell responses |
Non-Patent Citations (2)
Title |
---|
COHEN J: "Mounting a targeted strike on unwanted immune responses", SCIENCE, vol. 257, 7 August 1992 (1992-08-07), pages 751, XP002123149 * |
LENSCHOW D ET AL: "Long term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig", SCIENCE, vol. 257, 7 August 1992 (1992-08-07), pages 789 - 92, XP002021689 * |
Also Published As
Publication number | Publication date |
---|---|
CA2326671A1 (en) | 1999-11-11 |
JP2002513568A (en) | 2002-05-14 |
AU772239B2 (en) | 2004-04-22 |
EP1854884A2 (en) | 2007-11-14 |
ES2284251T3 (en) | 2007-11-01 |
US20100146648A1 (en) | 2010-06-10 |
EP1854884A3 (en) | 2009-07-29 |
DE69935318T2 (en) | 2007-11-15 |
US7432344B1 (en) | 2008-10-07 |
JP2011144205A (en) | 2011-07-28 |
EP1073737A2 (en) | 2001-02-07 |
WO1999057266A2 (en) | 1999-11-11 |
US20130078266A1 (en) | 2013-03-28 |
NZ527297A (en) | 2004-12-24 |
ATE355373T1 (en) | 2006-03-15 |
JP5706225B2 (en) | 2015-04-22 |
CA2326671C (en) | 2015-12-15 |
AU3721399A (en) | 1999-11-23 |
GB9809280D0 (en) | 1998-07-01 |
NZ507706A (en) | 2004-01-30 |
EP1073737B1 (en) | 2007-02-28 |
US9090708B2 (en) | 2015-07-28 |
US8097598B2 (en) | 2012-01-17 |
DE69935318D1 (en) | 2007-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999057266A3 (en) | Immunosuppression by blocking t cell co-stimulation signal 2 (b7/cd28 interaction) | |
Bellgrau et al. | A role for CD95 ligand in preventing graft rejection | |
Kabelitz | Apoptosis, graft rejection, and transplantation tolerance | |
NO984369D0 (en) | Immune modulation using B7-binding and CD40-binding molecules | |
CA2175577A1 (en) | Receptor on the surface of activated t-cells: acts-4 | |
EP2214337A3 (en) | Article comprising a wavelengh selective add-drop multiplexer | |
Carosella et al. | Immunotolerant functions of HLA-G | |
HK1025741A1 (en) | Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2co-stimulatory antigens. | |
JP2002513568A5 (en) | ||
WO1999002550A8 (en) | Ctl epitopes from ebv | |
DE60143799D1 (en) | GENETICALLY MANUFACTURED MHC MOLECULES | |
Sloan et al. | The effect of site of transplantation and histocompatibility differences on the survival of neural tissue transplanted to the CNS of defined inbred rat strains | |
CA2218737A1 (en) | Cytomodulating conjugates of members of specific binding pairs | |
Wecker et al. | Cellular mechanisms of rejection | |
Kato et al. | Specific acceptance of fetal bowel allograft in mice after combined treatment with anti-intercellular adhesion molecule-1 and leukocyte function-associated antigen-1 antibodies | |
Kimura et al. | Locally expressed CTLA4-Ig in a pancreatic beta-cell line suppresses accelerated graft rejection response induced by donor-specific transfusion | |
Holland | Atonement of Jesus Christ | |
Pabst | Scientific SWARM in the Southwest. | |
Naitove | Infrastracture and environment are themes of SPI... | |
SEKO et al. | Perforin-positive leukemic cell infiltration in the heart of a patient with T-cell prolymphocytic leukemia | |
CA2144716A1 (en) | Cloaking licence plate cover | |
Albright | Burmese daze. | |
Greenfield | The Tokyo Summit that wasn't. | |
Katzarova | Kosovo waits. | |
Hahn et al. | Redevelopment of the tolerance to pancreatic B-cells in BB rats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 507706 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref document number: 2326671 Country of ref document: CA Ref country code: CA Ref document number: 2326671 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999919418 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 37213/99 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1999919418 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09674462 Country of ref document: US |
|
WWG | Wipo information: grant in national office |
Ref document number: 37213/99 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 1999919418 Country of ref document: EP |